Treatment of Inflammatory Conditions Delivery of Interleukin-1 Receptor Antagonist Fusion Protein
Copyright © Targeted News Service 2024
2024-04-02
ALEXANDRIA, Virginia, April 2 -- REGENERON PHARMACEUTICALS, INC., Tarrytown, New York has been assigned a patent (No. US 11944666 B2, initially filed Sept. 2, 2022) developed by Eben Tessari, Lexington, Massachusetts, and John Paolini, Lexington, Massachusetts, for "Treatment of inflammatory conditions delivery of interleukin-1 receptor antagonist fusion protein." . . .